LILLY DESOUZA BURR

Lilly deSouza Burr is a distinguished Principal at Adjuvant Capital, a pioneering venture capital firm dedicated to advancing global health. At Adjuvant Capital, Lilly plays a pivotal role in identifying, evaluating, and supporting innovative companies that are developing life-saving health technologies and solutions for populations in low- and middle-income countries. Her expertise is crucial in driving investments that address some of the world's most pressing health challenges, including infectious diseases, maternal and child health, and neglected tropical diseases.

Her responsibilities at Adjuvant Capital encompass the full spectrum of venture capital activities, from rigorous due diligence and deal sourcing to investment execution and active portfolio management. Lilly is deeply involved in working with portfolio companies, providing strategic guidance to help them scale their impact and achieve their public health missions. Her commitment aligns perfectly with Adjuvant Capital's unique model, which blends financial returns with measurable health outcomes.

Before joining Adjuvant Capital, Lilly deSouza Burr built a robust career foundation focused on global health and development. She previously held significant roles at the Bill & Melinda Gates Foundation, where she contributed to initiatives aimed at accelerating product development for global health priorities. Her work at the Foundation provided her with invaluable insights into the complexities of global health ecosystems, product development pathways, and the critical need for sustainable financing mechanisms. Furthermore, her background includes experience in management consulting, where she advised clients across various sectors, honing her analytical and strategic problem-solving skills.

Lilly's investment focus at Adjuvant Capital spans a wide array of areas critical to global health equity. This includes novel vaccines, therapeutics, diagnostics, and other health technologies designed to be affordable, accessible, and appropriate for resource-limited settings. While specific individual investments are often part of a broader team effort, her contributions are integral to Adjuvant Capital's overall portfolio, which features companies developing solutions for diseases like tuberculosis, malaria, HIV, and various neglected tropical diseases. Her leadership helps ensure that capital is deployed effectively to foster innovations that can truly transform health outcomes on a global scale.

Through her work, Lilly deSouza Burr exemplifies a dedication to leveraging private capital for public good, making her a key figure in the global health investment landscape. Her strategic vision and deep understanding of both scientific innovation and market dynamics position her as a powerful advocate for health equity worldwide.